Drug Discontinuation

HPS Pharmacies wish to advise that Fresenius Kabi have announced the discontinuation of Fresofol® LCT formulations globally. Fresofol® MCT/LCT formulations will remain available.

A summary of the differences between the two formulations is shown below.

 

Fresofol® LCT Fresofol® MCT/LCT
Active ingredient Propofol Propofol
Strength 1% 1%
Presentation 20ml ampoule

50ml vial

100ml vial

20ml ampoule

50ml vial

100ml vial

Lipid base Long-chain triglycerides Medium chain triglycerides + long-chain triglycerides
Antimicrobial preservatives Nil Nil
Approved indications:
Induction of general anaesthesia Adults

Children >3 years

Adults

Children >1 month

Maintenance of general anaesthesia Adults

Children >3 years

Adults

Children >3 years

Children 1 month – 3 years (procedures not exceeding 60 minutes, unless alternative agents should be avoided

Sedation of ventilated patients receiving intensive care Adults Adults
Monitored conscious sedation for surgical and diagnostic procedures Adults Adults

Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies, or Fresenius Kabi on 1300 361 004.

Subscribe Knowledge Centre Updates

Enter your details to receive Knowledge Centre updates